Key Facts:
Identifai Genetics (ASX: ID1) commences trading on the ASX today after an IPO that raised A$10million at $0.20 per share.
Its flagship Windrose™ platform combines genomic sequencing, artificial intelligence and machine learning to assess selected inherited fetal conditions from a single maternal blood sample, without requiring a paternal sample.
Sample collection is designed to begin from approximately nine weeks of pregnancy.
IPO proceeds will support US laboratory readiness, assay validation, a planned multicentre clinical validation study and further product development.
CEO Eyal Miller called the listing an important step in translating Identifai's research into a product intended for use in prenatal care.
Sydney Tuesday 13th October 2026: Identifai Genetics Limited (ASX: ID1) begins trading on the Australian Securities Exchange today, 13 October 2026, following a successful Initial Public Offering raising A$10 million at A$0.20 per share. Aesir Corporate acted as Lead Manager.
The listing gives Identifai the capital to advance clinical validation of Windrose™ and prepare for its launch in the United States, the Company's first target commercialisation market. The technology originated from research by Professor Noam Shomron and Dr Tom Rabinowitz at Tel Aviv University. It is supported by an intellectual property portfolio of 11 patent families.
For some conditions, an earlier finding may give families and clinicians more time for genetic counselling, diagnostic investigation and coordination of specialist care.
Eyal Miller CEO said,
"Our ASX listing is an important step in translating Identifai's research into a product intended for use in prenatal care. We thank our shareholders for supporting the Company and welcome our new investors as we enter this next phase.
The United States is our first target commercial market. Our immediate priorities are progressing laboratory readiness, the planned clinical validation programme and staged product releases, while pursuing commercial partnerships
Our ambition is to make earlier, clinically relevant genetic information more accessible through a single maternal blood sample. Our immediate focus is on generating the evidence and establishing the laboratory capabilities needed to support that ambition. We look forward to keeping shareholders informed as we progress through these milestones."
Identifai's next steps include:
- advancing US laboratory readiness and assay validation, including applicable CLIA certification requirements
- progressing a planned US multicentre clinical validation study targeting approximately 600 participants
- developing the next-generation Windrose™+ programme
- pursuing commercial partnerships
The Company will update the market as material milestones are achieved.
About us:
Identifai Genetics Limited (ASX:ID1) is developing prenatal genetic screening technology that combines genomic analysis, artificial intelligence and machine learning to assess selected inherited conditions affecting the fetus. Its first product, Windrose™ is designed around a single maternal blood sample, without requiring a paternal sample in the intended screening workflow. The Company is focused on commercialising its technology in the United States first, with the aim of providing information earlier in pregnancy to support clinician-led investigation and care planning. Screening findings may require confirmatory diagnostic testing.
